Patents Assigned to Universite de Montpellier
  • Publication number: 20210252172
    Abstract: The present description relates to an emulsion comprising an amphiphilic compound, a first phase comprising droplets including at least one perfluorocarbon compound and a second phase, which is aqueous. The droplets have a diameter d4,3 of between 0.5 pm and 5.5 pm, and the at least one perfluorocarbon compound has a boiling point above 100° C. The present description also relates to such an emulsion for use as an improving agent in ultrasound ablation surgery (FIG. 3).
    Type: Application
    Filed: June 14, 2019
    Publication date: August 19, 2021
    Applicants: AVIGNON UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, SORBONNE UNIVERSITE, UNIVERSITE DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER
    Inventors: Christiane Contino-Pepin, Stéphane Desgranges, Nicolas Taulier
  • Patent number: 11072803
    Abstract: The invention relates to constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5 Kb by using an improved hybrid dual recombinant AAV vector system.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: July 27, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ DE NANTES, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, UNIVERSITÉ DE MONTPELLIER
    Inventors: Vasiliki Kalatzis, Achille Francois
  • Publication number: 20210221809
    Abstract: The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 22, 2021
    Applicants: AGV Discovery ENSCM, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite De Montpellier
    Inventors: Jean-François GUICHOU, Cédric BORIES, Clément GEOFFROY, Charline DUQUENNE, Muriel GELIN, Gilles LABESSE, Yannick BESSIN, Loic MATHIEU
  • Patent number: 11041858
    Abstract: The use of differentiation marker CD89 for the detection of cellular reservoirs of a mammalian immunodeficiency virus. Also the use of the differentiation marker CD89 for making a prognosis, diagnosing a remission, and evaluating the efficacy of treatment of the mammalian immunodeficiency. A multi-specific antibody that recognizes both at least one epitope of CD89 and at least one characteristic of the lymphocyte cells, a composition including the antibody, and the use of the antibody for treatment.
    Type: Grant
    Filed: September 30, 2017
    Date of Patent: June 22, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Monsef Benkirane, Gael Petitjean, Benjamin Descours
  • Patent number: 11033863
    Abstract: A filter for the filtration of a fluid, such as a liquid, includes or composed of a support element made of a porous ceramic material, the element having a tubular or parallelepipedal shape delimited by an external surface and including, in its internal portion, a set of adjacent channels with axes parallel to one another and separated from one another by walls of the porous inorganic material, wherein at least a portion of the channels and/or at least a portion of the external surface are covered with a porous separating membrane layer, wherein the layer is made of a material essentially composed of sintered grains of silicon carbide (SiC), and the weight content of elemental oxygen of the layer is less than 0.5%.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: June 15, 2021
    Assignees: SAINT-GOBAIN CENTRE DE RECHERCHES ET D'ETUDES EUROPEAN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER
    Inventors: Daniel Urffer, Christian Guizard
  • Patent number: 11021496
    Abstract: The present invention relates to mesoporous organosilica nanoparticles, the method of preparation thereof, and uses of the same in treatment by means of photodynamic therapy or in imaging.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: June 1, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, NANOMEDSYN
    Inventors: Jean Olivier Durand, Jimenez Chiara Mauriello, Sebastien Richeter, Laurence Raehm, Magali Gary-Bobo, Marcel Garcia, Marie Maynadier
  • Patent number: 11023621
    Abstract: The invention relates to a license-verification circuit for selectively activating one or more protected circuits (206) of a device (102) the license-verification circuit being capable of: deducing a device key from an identifier associated with the device (102); receiving a first license; decrypting the first license using the device key in order to extract a first verification code activating a first protected circuit by loading an activation code in an activation log (212) associated with the first protected circuit on the basis of a verification of the first verification code.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: June 1, 2021
    Assignees: Universite de Montpellier, Centre National de la Recherche Scientifique
    Inventors: Lionel Torres, Jérôme Rampon, Gaël Paul
  • Publication number: 20210154514
    Abstract: A method for destructing and valorizing an asbestos waste including the steps of: determining the asbestos mineralogical group contained in the waste, performing a treatment on the waste which includes of: an acid treatment when the waste comprises only a chrysotile, a base treatment when the waste comprises only an amphibole, the acid treatment followed by the base treatment when the asbestos waste includes a mixture of a chrysotile and an amphibole, and valorizing at least one of the products obtained on completion of the performing of the treatment. An embodiment also concerns a treatment of a chrysotile waste through an acid treatment followed by a thermal treatment.
    Type: Application
    Filed: August 21, 2018
    Publication date: May 27, 2021
    Applicants: Université de Montpellier, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ENSCM - ECOLE NATIONALE SUPERIEURE DE CHIMIE
    Inventors: Gaël TALBI, Olivier CAMBON, Martine CAMBON
  • Patent number: 11014918
    Abstract: The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: May 25, 2021
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Julien Santo
  • Patent number: 11014947
    Abstract: The present invention relates to a compound of formula (I) wherein: i is 0 or 1; j is 0 or 1; k is 0 or 1; R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R; R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; R3 is H and k=0 when j=1; or, when j=0, R3 is —C(O)R or -L-C(O)R; L, U and L? are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: May 25, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE D'AUVERGNE, UNIVERSITE DE MONTPELLIER
    Inventors: Philippe Brabet, David Cia, Laurent Guillou, Christian Hamel, Claire Vigor, Thierry Durand, Céline Crauste, Joseph Vercauteren
  • Publication number: 20210139447
    Abstract: The invention relates to compound of formula (I): in particular flavonoid derivatives (quercetin and catechin derivatives), for use in the prevention and/or the treatment of a disease or disorder involving both carbonyl and oxidative stresses.
    Type: Application
    Filed: July 12, 2019
    Publication date: May 13, 2021
    Applicants: Centre National de la Recherche Scientifique (CNRS), Universite De Montpellier, Ecole Nationale Superieure de Chimie, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Céline Crauste, Espérance Moine, Philippe Brabet, Thierry Durand, Joseph Vercauteren
  • Patent number: 11001634
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: May 11, 2021
    Assignees: GAMAMABS PHARMA, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIER
    Inventors: Thierry Chardès, Olivier Dubreuil, André Pelegrin, Christel Larbouret, Jean-François Prost, Jean-Marc Barret, Stéphane Degove
  • Publication number: 20210130405
    Abstract: The present invention relates to peptidomimetic macrocycles comprising at least one macrocycle-forming linker and an amino acid sequence chosen from the group consisting of: i) an amino acid sequence with at least about 50%, 60%, 70%, 80%, 90%, or 95% sequence identity to a human sequence IRAK2 54-71 (SEQ ID No 1) and 100% identity with the amino acids in the positions 5-6, 9-11, 14-15 or ii) an amino acid sequence with at least about 50%, 60%, 70, 80%, 90%, or 95% sequence identity to a human sequence IRAKM 66-83 (SEQ ID No2) and 100% identity with the amino acids in the positions 5-6, 9-11, 13-14, wherein the peptidomimetic macrocycle comprises an ?-helix and at least two natural or two non-natural amino acids crosslinked by a macrocycle-forming linker. It also concerns method of preparation of said peptidomimetic macrocycles and uses thereof, pharmaceutical composition and uses thereof, in particular as inhibitors of inflammatory pathways.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 6, 2021
    Applicants: Universite de Montpellier, Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Montpellier, Institut National de la Sante et de la Recherche Medicale (INSERM), Ecole Nationale Superieure de Chimie de Montpellier - ENSCM
    Inventors: Guillaume Laconde, Muriel Amblard-Caussil, Jean Martinez, Christian Jorgensen, Florence Apparailly-Sechan, Isabelle Duroux-Richard
  • Patent number: 10995089
    Abstract: The present invention concerns a compound of formula (I): H or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 4, 2021
    Assignees: AGV DISCOVERY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE MONTPELLIER
    Inventors: Jean-François Guichou, Cédric Bories, Clément Geoffroy, Charline Duquenne, Muriel Gelin, Gilles Labesse, Yannick Bessin, Loic Mathieu
  • Publication number: 20210122732
    Abstract: A compound of formula (Ie): wherein Y1 represents an aryl group, X2 represents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH3)NH— group, a —C(OH)(CH2OH)—, a group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO2— group, or a —SO2—NH— group, Y2 represents a hydrogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a —CHC(OH)2, a COORf, wherein Rf represents a hydrogen atom or a (C1-C4)alkyl group, a morpholinyl group, a dihydropyranyl group, a group, a group, a —PO(ORf)(OR?f) group, wherein Rf and R?f independently represents a hydrogen atom or a (C1-C4)alkyl group, an oxetanyl group, a —Si(CH3)3 group, a —NHCOO—(C1-C4)alkyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.
    Type: Application
    Filed: July 9, 2019
    Publication date: April 29, 2021
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Julien SANTO, Cécile APOLIT
  • Publication number: 20210115085
    Abstract: A continuous, solvent-free and non-enzymatic method for synthesizing a compound of formula (I): Ra-POLYPEP-Rc (I) wherein: POLYPEP is a poly-amino acid compound, Ra and Rc are as specified, the method including the steps of: a) feeding an extrusion reactor with (1) a compound of formula (II) Ra-PEPNt-Rg (II) wherein; PEPNt is a mono- or a poly-amino acid compound, Ra and Rg are as specified, and (2) a compound of formula (III) H-PEPCt-Rc (III) wherein: PEPCt is a mono- or a poly-amino acid compound, and Rc is as defined in the absence of any solvent, so that the compound of formula (II) and the compound of formula (III) react together for generating a compound of formula (I), and b) collecting the compound of formula (I) from the extrusion reactor.
    Type: Application
    Filed: February 12, 2019
    Publication date: April 22, 2021
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER, ECOLE DES MINES D'ALES, ASSOCIATION POUR LA RECHERCHE ET LE DEVELOPPEMENT DES METHODES ET PROCESSUS INDUSTRIELS
    Inventors: Yves YEBOUE, Benjamin GALLARD, Nicolas LE MOIGNE, Frédéric LAMATY, Jean MARTINEZ, Thomas-Xavier METRO
  • Patent number: 10981874
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: April 20, 2021
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Jamal Tazi, Florence Mahuteau, Romain Najman
  • Patent number: 10975063
    Abstract: The manufacture of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof, and use of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof, for treating various conditions, and/or inhibiting replication of HIV-1 in a patient infected with HIV-1, by administering to a patient in need thereof an effective quantity of 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: April 13, 2021
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Florence Mahuteau, Romain Najman, Jamal Tazi
  • Patent number: 10969391
    Abstract: The present invention relates to methods for diagnosing hematological cancers. In particular, the present invention relates to a method for diagnosing a hematological cancer in a patient comprising i) detecting the presence of CD45RARO NK cells in a sample obtained from the patient and ii) and concluding that the patient suffers from a hematological cancer when the presence of CD45RARO NK cells is detected in the sample and the presence of at least one phenotypic marker indicates the nature of the haematological cancer.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: April 6, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: Martin Villalba Gonzalez, Ewelina Krzywinska
  • Publication number: 20210087145
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Application
    Filed: December 7, 2020
    Publication date: March 25, 2021
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal TAZI, Romain NAJMAN, Florence MAHUTEAU, Didier SCHERRER, Karim CHEBLI, Michael HAHNE